Since beginning of 2019, the InvestHorizon accelerator has supported for free over 500 deeptech companies with various services to improve their investment readiness, i.e., personalised coaching, pitching academies and events, bootcamps, online courses and webinars. The aim was to bring them closer to their goal of raising Series A investment and boost their investor relations.
Today, we can proudly announce that after passing through our accelerator many alumni successfully raised investment, summing up to an overall fundraising of more than 250 million €.
PhagoMed (BioNTech R&D Austria after acquisition) has recently announced their acquisition by BioNTech SE.
The Austrian biotech startup is developing novel disease- targeted anti-bacterials. Their technology combats the urgent problem of antimicrobial resistance (AMR), which is being accelerated by the misuse of antibiotics. According to the WHO, AMR is one of the biggest threats to global health.
InvestHorizon is an accelerator programme designed to facilitate the access to Series A funding for selected deep tech companies and help them boost their investment readiness and investor relations. 500 SMEs have been already accelerated. Join our community now to benefit from all our open services.
This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.
We also use analytics services to help us understand where our audience is coming from. To opt-out click 'More information'.